Decoy Therapeutics Inc. (DCOY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Decoy Therapeutics Inc. (DCOY) has a cash flow conversion efficiency ratio of -0.193x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.14 Million) by net assets ($5.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Decoy Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Decoy Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Decoy Therapeutics Inc. for a breakdown of total debt and financial obligations.
Decoy Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Decoy Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Noratis AG
XETRA:NUVA
|
0.070x |
|
CubicFarm Systems Corp
V:CUB
|
0.012x |
|
Pembroke VCT PLC
LSE:PEMB
|
-0.007x |
|
Softimat S.A.
BR:SOFT
|
0.311x |
|
Sky Gold Corp
V:SKYG
|
-0.102x |
|
Norden Crown Metals Corp
V:NOCR
|
-3.361x |
|
Singularity Future Technology Ltd
NASDAQ:SGLY
|
-4.756x |
|
Petrotal Corp
LSE:PTAL
|
0.035x |
Annual Cash Flow Conversion Efficiency for Decoy Therapeutics Inc. (2014–2025)
The table below shows the annual cash flow conversion efficiency of Decoy Therapeutics Inc. from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Decoy Therapeutics Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.89 Million | $-4.83 Million | -0.820x | +72.62% |
| 2024-12-31 | $1.51 Million | $-4.53 Million | -2.994x | -23.21% |
| 2023-12-31 | $5.29 Million | $-12.85 Million | -2.430x | -43.39% |
| 2022-12-31 | $10.38 Million | $-17.60 Million | -1.694x | -543.23% |
| 2021-12-31 | $38.72 Million | $-10.20 Million | -0.263x | +43.39% |
| 2020-12-31 | $22.16 Million | $-10.31 Million | -0.465x | +57.48% |
| 2019-12-31 | $10.58 Million | $-11.58 Million | -1.094x | +56.95% |
| 2018-12-31 | $9.28 Million | $-23.60 Million | -2.542x | -166.91% |
| 2017-12-31 | $29.11 Million | $-27.72 Million | -0.952x | -76.27% |
| 2016-12-31 | $59.32 Million | $-32.05 Million | -0.540x | -140.12% |
| 2015-12-31 | $92.19 Million | $-20.75 Million | -0.225x | -121.23% |
| 2014-12-31 | $-6.54 Million | $-6.93 Million | 1.060x | -- |
About Decoy Therapeutics Inc.
Decoy Therapeutics Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture pe… Read more